Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 41%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson reported operational sales growth of 11.5% in 4Q 2025, excluding the significant impact of generic competition affecting Stelara, indicating strong performance driven by its innovative medicine and medtech divisions. The company's updated revenue estimates for 2026 highlight projected total revenue of $100.42 billion, reflecting positive adjustments due to impressive growth in key products like Tremfya and Rybrevant. With JNJ's stock appreciating approximately 30% since July 2025 and the positive momentum expected to continue into 2026, the firm’s favorable outlook is supported by robust earnings revisions and a strong product pipeline.

Bears say

Johnson & Johnson faces significant challenges due to the impending loss of patent exclusivity, which typically results in rapid declines in sales as competitors introduce generics and biosimilars. The company’s outlook is further pressured by the potential disappointing launches of newer products and critical data readouts from its pipeline, which raise concerns about overall sales and earnings. Additionally, ongoing litigation risks, particularly regarding talc-related lawsuits, combined with macroeconomic uncertainties such as U.S. drug pricing reform, may deter investor interest and contribute to share volatility.

JNJ has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 41% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 17 analysts, JNJ has a Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $231.65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $231.65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.